文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

准备长效 PrEP 给药:借鉴口服 PrEP 的经验。

Preparing for long-acting PrEP delivery: building on lessons from oral PrEP.

机构信息

Departments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, Washington, USA.

Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro, Brazil.

出版信息

J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26103. doi: 10.1002/jia2.26103.


DOI:10.1002/jia2.26103
PMID:37439077
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10339005/
Abstract

INTRODUCTION: With recent approvals of long-acting (LA) HIV pre-exposure prophylaxis (PrEP) in the form of injectable cabotegravir and the dapivirine ring, programmes need to consider how to optimize the delivery of PrEP methods, including by leveraging lessons from the past decade of oral PrEP delivery. DISCUSSION: Framed around differentiated service delivery building blocks, the major considerations for the delivery of LA PrEP are how to reach the populations who would most benefit from PrEP, where to locate PrEP services, how to reduce the user burden of accessing and continuing with PrEP, and how to integrate PrEP with other services. Demand creation for LA PrEP and education about new LA PrEP options should be co-developed with communities and be positively framed. Client-facing clinical decision support tools provide information about HIV prevention and PrEP options in non-technical ways and can support their informed decision-making about PrEP. Training for providers is needed to increase their ability to ask about sexual and drug use behaviours in a non-judgmental and comfortable manner as part of risk assessment, discuss harm reduction strategies and counsel about available PrEP options that fit clients' circumstances and needs. PrEP adherence support should include supportive counselling and be tailored to address an individual's particular barriers and needs. Reminders through text messaging or calls can foster PrEP persistence, given the narrow the window around dosing for injectable cabotegravir. Strategies are needed to expand PrEP delivery options, including telePrEP, pharmacy-based PrEP, key population-led services and mobile venues. Integrated delivery models are needed which include sexually transmitted infection testing and treatment, contraception for cis-women not desiring to become pregnant, PrEP for pregnant women in high HIV prevalence settings, and gender-affirming hormones and support for transgender persons. CONCLUSIONS: The outcome of expanding PrEP options through LA PrEP formulations is to increase PrEP coverage, adherence, persistence and effectiveness by offering a choice of PrEP that meets the needs of persons who would benefit from PrEP. The lessons learned from the delivery of oral PrEP about demand creation, informed client decision-making, provider training, adherence support and service delivery model are relevant to the delivery of LA PrEP and integration with other services.

摘要

引言:随着长效(LA)HIV 暴露前预防(PrEP)药物注射用卡替拉韦和阴道避孕环的相继获批,各项目需要考虑如何优化 PrEP 方法的提供,包括借鉴过去十年口服 PrEP 提供方面的经验教训。

讨论:围绕差异化服务提供的组成部分,LA PrEP 提供的主要考虑因素包括如何接触最能从 PrEP 中受益的人群、在何处提供 PrEP 服务、如何降低获得和继续使用 PrEP 的用户负担,以及如何将 PrEP 与其他服务整合。LA PrEP 的需求创造和新 LA PrEP 选择的教育应与社区共同制定,并以积极的方式呈现。面向客户的临床决策支持工具以非技术性的方式提供有关 HIV 预防和 PrEP 选择的信息,可支持他们在知情的情况下做出有关 PrEP 的决策。需要对提供者进行培训,以提高他们在风险评估中以非评判和舒适的方式询问性行为和药物使用行为的能力,讨论减少伤害策略,并提供适合客户情况和需求的可用 PrEP 选择的咨询。PrEP 依从性支持应包括支持性咨询,并根据个人的特定障碍和需求进行调整。鉴于注射用卡替拉韦的剂量窗口较窄,通过短信或电话提醒可以促进 PrEP 的持续使用。需要扩大 PrEP 提供选择的策略,包括远程 PrEP、基于药房的 PrEP、重点人群主导的服务和流动场所。需要采用综合提供模式,包括性传播感染检测和治疗、不希望怀孕的顺性别女性的避孕措施、高 HIV 流行地区孕妇的 PrEP 以及跨性别者的性别肯定激素和支持。

结论:通过 LA PrEP 制剂扩大 PrEP 选择的结果是通过提供满足可能从 PrEP 中受益的人群需求的 PrEP 选择,来提高 PrEP 的覆盖率、依从性、持续性和效果。从口服 PrEP 提供方面获得的关于需求创造、知情客户决策、提供者培训、依从性支持和服务提供模式的经验教训与 LA PrEP 的提供和与其他服务的整合相关。

相似文献

[1]
Preparing for long-acting PrEP delivery: building on lessons from oral PrEP.

J Int AIDS Soc. 2023-7

[2]
HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery.

J Int AIDS Soc. 2019-7

[3]
Need for informed providers: exploring LA-PrEP access in focus groups with PrEP-indicated communities in Baltimore, Maryland.

BMC Public Health. 2024-5-8

[4]
Lessons learnt from daily oral PrEP delivery to inform national planning for PrEP ring introduction for women in low-income and middle-income countries: a qualitative inquiry of international stakeholders.

BMJ Glob Health. 2024-5-7

[5]
The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery.

AIDS Behav. 2023-11

[6]
Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study.

JMIR Public Health Surveill. 2023-4-19

[7]
The importance of the "how": the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment.

J Int AIDS Soc. 2023-7

[8]
CROI 2024: Global Epidemiology and Prevention of HIV and Other Sexually Transmitted Diseases.

Top Antivir Med. 2024-7-17

[9]
Advancing the use of Long-Acting Extended Delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations.

J Int AIDS Soc. 2023-7

[10]
Stand-alone model for delivery of oral HIV pre-exposure prophylaxis in Kenya: a single-arm, prospective pilot evaluation.

J Int AIDS Soc. 2023-6

引用本文的文献

[1]
Oral PrEP use and intention to use long-acting PrEP regimens among MSM accessing PrEP via governmental and non-governmental provision pathways, 20 European countries, October 2023 to April 2024.

Euro Surveill. 2025-8

[2]
PrEP choice in the real world: Results of a prospective cohort study describing uptake and use patterns of oral PrEP and the dapivirine vaginal ring among women in sub-Saharan Africa.

J Int AIDS Soc. 2025-7

[3]
Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.

J Int AIDS Soc. 2025-7

[4]
Measuring mobility in HIV research in sub-Saharan Africa: a scoping review.

J Int AIDS Soc. 2025-6

[5]
Crowdsourcing Ideas for the Implementation of Long-Acting Injectable PrEP among Sexual Minority Men in Chicago through an Innovation Tournament.

Implement Sci Commun. 2025-5-26

[6]
Preference for Service Delivery for Long-Acting Pre-exposure Prophylaxis for HIV Infection Among Pregnant and Breastfeeding Women in South Africa and Botswana.

AIDS Behav. 2025-5-21

[7]
Performance of Adherence Measures for Oral, Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Systematic Review.

AIDS Behav. 2025-5-6

[8]
A case study of the co-creation of the PrEP-SIC: a roadmap to support introduction of pre-exposure prophylaxis into new settings.

BMC Health Serv Res. 2025-5-1

[9]
Community PrEP delivery for adolescent girls and young women: insights from the DREAMS PrEP Choice Study in Johannesburg, South Africa.

Front Reprod Health. 2025-4-4

[10]
Setting up a pharmacy HIV pre-exposure prophylaxis delivery model: Lessons and recommendations for implementation.

South Afr J HIV Med. 2025-3-25

本文引用的文献

[1]
Preferences for pre-exposure prophylaxis (PrEP) among sexual and gender minorities: a discrete choice experiment in Brazil.

Lancet Reg Health Am. 2023-2-6

[2]
HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention.

J Infect Dis. 2022-12-13

[3]
Factors associated with long-term HIV pre-exposure prophylaxis engagement and adherence among transgender women in Brazil, Mexico and Peru: results from the ImPrEP study.

J Int AIDS Soc. 2022-10

[4]
HIV Risk Perception and Pre-Exposure Prophylaxis (PrEP) Awareness Among Transgender Women from Mexico.

AIDS Behav. 2023-3

[5]
Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.

Lancet HIV. 2022-10

[6]
Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial.

Lancet HIV. 2022-7

[7]
Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.

Lancet HIV. 2022-8

[8]
Targeted Implementation of HIV Self-Testing Increases Testing Uptake Among Partners of Index Persons Known to Have HIV in Kenya.

J Acquir Immune Defic Syndr. 2022-8-15

[9]
Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis.

Lancet HIV. 2022-4

[10]
Low PrEP adherence despite high retention among transgender women in Brazil: the PrEParadas study.

J Int AIDS Soc. 2022-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索